HRP20201609T1 - Biorazgradivi hidrogelovi netopivi u vodi bazirani na polietilenglikolu - Google Patents

Biorazgradivi hidrogelovi netopivi u vodi bazirani na polietilenglikolu Download PDF

Info

Publication number
HRP20201609T1
HRP20201609T1 HRP20201609TT HRP20201609T HRP20201609T1 HR P20201609 T1 HRP20201609 T1 HR P20201609T1 HR P20201609T T HRP20201609T T HR P20201609TT HR P20201609 T HRP20201609 T HR P20201609T HR P20201609 T1 HRP20201609 T1 HR P20201609T1
Authority
HR
Croatia
Prior art keywords
group
hydrogel according
parts
hyp
biodegradable hydrogel
Prior art date
Application number
HRP20201609TT
Other languages
English (en)
Inventor
Harald Rau
Ulrich Hersel
Mathias Krusch
Dirk Vetter
Tobias Voigt
Original Assignee
Ascendis Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma A/S filed Critical Ascendis Pharma A/S
Publication of HRP20201609T1 publication Critical patent/HRP20201609T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Colloid Chemistry (AREA)

Claims (37)

1. Biorazgradivi hidrogel netopiv u vodi baziran na poli(etilenglikolu), koji sadrži dijelove okosnice glavnog lanca povezane zajedno preko dijelova poprečno umreženih povezivača, pri čemu svaki dio poprečno umreženih povezivača završava s najmanje dvije hidrolitički razgradive veze, naznačen time, da dijelovi glavne okosnice imaju molekularnu masu u rasponu od 1 kDa do 20 kDa i imaju strukturu C*-(A-Hyp)x, gdje C* je razgranata jezgra, A je polimerni lanac na bazi poli(etilenglikola), Hyp je hiper-razgranati dendritički dio skupine, x je cijeli broj od 3 do 16; te pritom hiper-razgranati dendritički dio skupine nadalje obuhvaća reaktivne funkcionalne skupine i međupovezane funkcionalne skupine.
2. Biorazgradivi hidrogel prema patentnom zahtjevu 1, naznačen time, da razgranata jezgra obuhvaća poliakohol, oligoalkohol, poliamin ili oligoamin u spojenom obliku.
3. Biorazgradivi hidrogel prema patentnom zahtjevu 1 ili 2, naznačen time, da razgranata jezgra obuhvaća pentaeritritol, tripentaeritritol, heksaglicerin, sukrozu, sorbitol, fruktozu, manitol, glukozu, celulozu, amilozu, škrob, hidroksilakilni škrob, polivinilalkohol, dekstran, hijaluronan, trilizin, tetralizin, pentalizin, heksalizin, heptalizin, oktalizin, nonalizin, dekalizin, undekalizin, dedekalizin, tridekalizin, tetradekalizin, pentadekalizin, oligolizin, polietilenimin ili polivinilamin u spojenom obliku.
4. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da razgranata jezgra obuhvaća pentaeritritol, trilizin, tetralizin, pentalizin, heksalizin, heptalizin, oligolizin, PEI male molekularne mase, heksaglicerin ili tripentaeritritol u spojenom obliku.
5. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da x je cijeli broj od 4 do 8.
6. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da svaka Hyp ima molekularnu masu u rasponu od 0,4 kDa do 4 kDa.
7. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da dijelovi poprečnog povezivača imaju molekularnu masu u rasponu od 0,5 kDa do 5 kDa, te time da je svaki dio poprečnog povezivača baziran na PEG.
8. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da svaki dio glavne okosnice obuhvaća u zbroju najmanje 16 međupovezanih biorazgradivih i reaktivnih funkcionalnih skupina.
9. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da dijelovi glavne okosnice imaju kvaterni ugljik sljedeće formule: C(A-Hyp)4, u kojoj je svaki A neovisno polimerni lanac na bazi poli(etilenglikola), koji je završno priključen na kvaterni ugljik pomoću permanentne kovalentne veze i udaljeni kraj polimernog lanca je kovalentno povezan s dendritičkim dijelom Hyp-skupine, dok svaki dio dendritičke Hyp-skupine posjeduje najmanje četiri funkcionalne skupine koje predstavljaju međupovezane i reaktivne funkcionalne skupine.
10. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je svaki A neovisno odabran iz formule: –(CH2)nl(OCH2CH2)nX-, gdje nl je 1 ili 2; n je cijeli broj u rasponu od 5 do 50; i X je kemijska funkcionalna skupina koja kovalentno povezuje A i Hyp.
11. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da Hyp uvijek posjeduje najmanje tri grane i najmanje četiri reaktivne funkcionalne skupine.
12. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da Hyp je hiper-razgranati polipeptid.
13. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da Hyp sadrži lizine u spojenom obliku.
14. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da se svaki dio Hyp-skupine sastoji od 5 do 32 lizina.
15. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da Hyp sadrži heptalizinil.
16. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da dijelovi glavne okosnice obuhvaćaju razgranatu jezgru sljedeće formule: [image] u kojoj crtkana linija označava priključenje na preostatak od dijela glavne okosnice.
17. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 16, naznačen time, da dijelovi glavne okosnice obuhvaćaju strukturu sljedeće formule: [image] u kojoj n je cijeli broj od 5 do 50 i crtkana linija označava priključenje na ostatak od molekule.
18. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 17, naznačen time, da dijelovi glavne okosnice obuhvaćaju hiper-razgranate dijelove Hyp-skupine sljedeće formule: [image] u kojoj crtkane linije označavaju priključenje na ostatak molekule i ugljikovi atomi koji su označeni sa zvjezdicama, označavaju S-konfiguraciju.
19. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 18, naznačen time, da dijelovi glavne okosnice sadrže najmanje jedan držač razmaka sljedeće formule: [image] u kojoj jedna od crtkanih linija označava priključenje na hiper-razgranati dio Hyp-skupine, a druga crtkana linija označava priključenje na ostatak molekule; i pritom m je cijeli broj od 2 do 4.
20. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 19, naznačen time, da dijelovi glavne okosnice sadrže najmanje jedan držač razmaka sljedeće formule: [image] u kojoj neoznačena crtkana linija pokazuje priključenje na Hyp; crtkana linija koja je označena sa zvjezdicom pokazuje vezu između hidrogela i N iz tiosukcinimidne skupine, i pritom p je cijeli broj od 0 do 10.
21. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 20, naznačen time, da su dijelovi glavne okosnice povezani zajedno preko dijelova poprečnog povezivača koji sadrži sljedeću strukturu: [image] u kojoj q je cijeli broj od 3 do 100.
22. Biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 21, naznačen time, da se dijelovi poprečnog povezivača sastoje od PEG koji je simetrično povezan preko esterskih veza na dva alfa, omega-alifatska dikarboksilna držača razmaka koji su omogućeni preko dijelova glavne okosnice spojenih na hiper-razgranati dendritički dio skupine preko permanentnih amidnih veza.
23. Konjugat koji obuhvaća hidrogel prema bilo kojem od patentnih zahtjeva 1 do 22, naznačen time, da je hidrogel sastavljen od dijelova glavne okosnice koji su međupovezani pomoću hidrolitički razgradivih veza i dodatno prenosi permanentne veze do molekula držača razmaka ili blokatorskih skupina ili do njihovih kombinacija.
24. Konjugat koji obuhvaća hidrogel prema bilo kojem od patentnih zahtjeva 1 do 22, naznačen time, da je hidrogel sastavljen od dijelova glavne okosnice koji su međupovezani pomoću hidrolitički razgradivih veza i dodatno prenosi permanentne veze do liganda ili do kelatnih skupina.
25. Konjugat prema patentnom zahtjevu 24, naznačen time, da su ligandi odabrani iz skupine koja se sastoji od sljedećih: 4-aminobenzamidin, 3-(2'-aminobenzhidriloksi)tropan, ε-aminokaproil-p-klorobenzilamid, 1-amino-4-[3-(4,6-diklorotriazin-2-ilamino)-4-sulfofenilamino]antrakinon-2-sulfonska kiselina, 2-(2'-amino-4'-metilfeniltio)-N,N-dimetilbenzilamin-dihidroklorid, angiopoietin-1, aptameri, arotinoidna kiselina, avidin, biotin, kalmodulin, kokaetilen, citosporon B, N,N-diheksil-2-(4-fluorofenil)indol-3-acetamid, N,N-dipropil-2-(4-klorofenil)-6,8-dikloro-imidazo[1,2-a]piridin-3-acetamid, 5-fluoro-2'-deoksiuridin-5'-(p-aminofenil)monofosfat, S-heksil-L-glutation, (S,S)-4-fenil-α-(4-feniloksazolidin-2-iliden)-2-oksazolin-2-acetonitril, Pro-Leu-Gly-hidroksamat, 2-(4-(2-trifluorometil)fenil)piperidin-1-karboksamido)benzojeva kiselina, trimetil(m-aminofenil)amonijev klorid, urokortin III, kofaktori kao adenozin-trifosfat, s-adenozil-metionin, askorbinska kislina, kobalamin, koenzim A, koenzim B, koenzim M, koenzim Q, koenzim F420, citidin-trifosfat, flavin-mononukleotid, flavin-adenin-dinukleotid, glutation, haem, lipoamid, menakvinon, metanofuran, metilkobalamin, molibdopterin, NAD+, NADP+, nukleotidni šećeri, 3'-fosfoadenozin-5'-fosfosulfat, piridoksal-fosfat, polihistidini, pirolokinolin-kvinon, riboflavin, streptavidin, tetrahidrobiopterin, tetrahidrometanopterin, tetrahidrofolna kiselina, biotin-karboksil-nosivi protein (BCCP), vezivni protein kitina, FK506 vezivni proteini (FKBP), FLAG-oznaka, zeleni fluorescentni protein, glutation-S-transferaza, hemagglutinin (HA), vezivni protein maltoze, mik-oznaka, NusA, epitop proteina C, S-oznaka, strep-oznaka, tioredoksini i afinitetni skelni proteini.
26. Konjugat prema patentnom zahtjevu 24, naznačen time, da su kelatne skupine odabrane iz skupine koja se sastoji od sljedećih: 2,2'-bipiridil, 1,2-bis(2-aminofenoksi)etan-N,N,N',N'-tetraoctena kiselina, deferoksamin-mesilat, deferiferikrom, dietilentriamin, 2,3-dimerkapto-1-propanol, dimerkapto-sukcinska kiselina, dimetilglioksin, 2,2'-dipiridil, etilen-diamin, etilendiamintetra (metilenfosfonska kiselina), 1,2-bis(2-amino-5-bromofenoksi)etan-N,N,N'N'-tetraoctena kiselina, 8-hidroksikinolin, iminodiacetat, iminodi(metilfosfonska kiselina), L-mimozin, nitrilotriacetat, oksalat, 1,10-fenantrolin, fitinska kiselina, tartrat, 1,4,7,10-tetraazaciklododekan-1,4,7,10-tetraacetat, N,N,N',N'-tetrakis(2-piridilmetil)etilendiamin, triaminotrietilamin, iminodioctena kiselina, tiourea i 2-pikolilamin.
27. Predlijek povezan s nosačem, naznačen time, da obuhvaća biorazgradivi hidrogel prema bilo kojem od patentnih zahtjeva 1 do 22 kao nosač, pri čemu jedan broj permanentnih veza dijelova glavne okosnice, postoji za svaki tranzijentni povezivač L predlijeka, na kojega je kovalentno priključen biološki aktivni dio skupine D.
28. Predlijek povezan s nosačem prema patentnom zahtjevu 27, naznačen time, da tranzijentna veza između D i L je karbamatna, karbonatna, amidna ili esterska veza.
29. Predlijek povezan s nosačem prema patentnom zahtjevu 27 ili 28, naznačen time, da tranzijentni povezivač L predlijeka obuhvaća dio L1 koji je supstituiran s dijelom L2 i pritom je L2 povezan sa skupinom nosača Z, pri čemu je to hidrogel prema bilo kojem od patentnih zahtjeva 1 do 22.
30. Predlijek povezan s nosačem prema bilo kojem od patentnih zahtjeva 27 do 29, naznačen time, da -L je nebiološki aktivni dio povezivača -L1 koji je predstavljen sljedećom formulom (VI): [image] gdje crtkana linija označava priključenje na primarnu ili sekundarnu amino skupinu od biološki aktivnog dijela skupine D koji sadrži amin, pomoću stvaranja amidne veze; i pritom X, X1, X2, R1, R1a, R2, R2a, R3 i R3a iz formule (VI), imaju sljedeće značenje: X je C(R4R4a); N(R4); O; C(R4R4a)-C(R5R5a); C(R5R5a)-C(R4R4a); C(R4R4a)-N(R6); N(R6)-C(R4R4a); C(R4R4a)-O; ili O-C(R4R4a); X1 je C; ili S(O); X2 je C(R7, R7a); ili C(R7, R7a)-C(R8, R8a); R1, R1a, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6, R7, R7a, R8, R8asu neovisno odabrani iz skupine koja se sastoji od H; i C1-4-alkila; prema potrebi, jedan ili više od parova R1a/R4a, R1a/R5a, R4a/R5a, R7a/R8a, tvore kemijsku vezu; prema potrebi su jedan ili više od parova R1/R1a, R2/R2a, R4/R4a, R5/R5a, R7/R7a, R8/R8a spojeni zajedno s atomom na kojega su priključeni, za tvorbu C3-7-cikloalkila; ili 4-7-članog heterociklila; prema potrebi su jedan ili više od parova R1/R4, R1/R5, R1/R6, R4/R5, R7/R8, R2/R3 spojeni zajedno s atomima na koje su priključeni, za tvorbu prstena A; prema potrebi su R3/R3a spojeni zajedno s dušikovim atomom na kojega su priključeni, za tvorbu 4-7-člang heterocikla; A je odabran iz skupine koja se sastoji od sljedećih: fenil; naftil; indenil; indanil; tetralinil; C3-10-cikloalkil; 4-7-člani heterociklil; i 9-11-člani heterobiciklil; i pritom je L1 supstituiran s jednom skupinom L2-Z te je prema potrebi dodatno supstituiran, uz uvjet da vodik koji je označen sa zvjezdicom u formuli (VI), nije zamijenjen supstituentom; pri čemu L2 je jednostruka kemijska veza ili držač razmaka; i Z je odgovarajući hidrogel prema bilo kojem od patentnih zahtjeva 1 do 21.
31. Predlijek povezan s nosačem prema bilo kojem od patentnih zahtjeva 27 do 30, naznačen time, da je biološki aktivni dio skupine odabran iz skupine koja se sastoji od polipeptida, proteina, oligonukleotida te biološki aktivnih ostataka male molekule.
32. Predlijek povezan s nosačem prema bilo kojem od patentnih zahtjeva 27 do 31, naznačen time, da je L2 priključen na Z preko terminalne skupine koja ima sljedeću strukturu: [image] gdje crtkane linije označavaju odgovarajuće priključenje na L2 odnosno Z.
33. Farmaceutski pripravak, naznačen time, da obuhvaća predlijek prema bilo kojem od patentnih tzahtjeva 27 do 32 ili njegovu farmaceutski prihvatljivu sol, zajedno s farmaceutski prihvatljivim pomoćnim sredstvom.
34. Predlijek prema bilo kojem od patentnih zahtjeva 27 do 32, ili farmaceutski pripravak prema patentnom zahtjevu 33, naznačen time, da se upotrebljava kao medikament.
35. Postupak za proizvodnju hidrogela, naznačen time, da obuhvaća sljedeći korak: (a) reakciju reagensa glavne okosnice koji ima sljedeću formulu: [image] u kojoj je n cijeli broj od 3 do 100; s reagensom poprečnog povezivača sljedeće formule: [image] pri čemu q je cijeli broj od 3 do 100: svaki m neovisno predstavlja cijeli broj od 2 do 4; u odnosu amin/aktivni ester u iznosu od 2:1 do 1,05:1, koji rezultira u opterećenju hidrogela od 0,02 do 2 mmol amina po gramu hidrogela; te time, da se reagensi rastapaju u aprotičkom otapalu u prisutnosti prikladne lužine.
36. Hidrogel, naznačen time, da se može dobiti putem postupka prema patentnom zahtjevu 35.
37. Hidrogel prema bilo kojem od patentnih zahtjeva 1 do 21 ili 36, naznačen time, da se nalazi u obliku obloge, prepleta, stenta ili mikročestica koje se dobivaju pomoću usitnjavanja putem mehaničkih postupaka kao što su miješanje, drobljenje, rezanje stlačivanjem ili mljevenje, te prema potrebi prosijavanje.
HRP20201609TT 2009-07-31 2020-10-07 Biorazgradivi hidrogelovi netopivi u vodi bazirani na polietilenglikolu HRP20201609T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09167026 2009-07-31
EP09172339 2009-10-06
PCT/EP2010/061155 WO2011012715A1 (en) 2009-07-31 2010-07-30 Biodegradable polyethylene glycol based water-insoluble hydrogels
EP10737075.1A EP2459220B1 (en) 2009-07-31 2010-07-30 Biodegradable polyethylene glycol based water-insoluble hydrogels

Publications (1)

Publication Number Publication Date
HRP20201609T1 true HRP20201609T1 (hr) 2021-01-08

Family

ID=43027631

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201609TT HRP20201609T1 (hr) 2009-07-31 2020-10-07 Biorazgradivi hidrogelovi netopivi u vodi bazirani na polietilenglikolu

Country Status (23)

Country Link
US (1) US11559482B2 (hr)
EP (2) EP3782649A1 (hr)
JP (1) JP5904941B2 (hr)
KR (1) KR101770844B1 (hr)
CN (1) CN102573913B (hr)
AU (1) AU2010277556B2 (hr)
BR (1) BR112012002280B1 (hr)
CA (1) CA2769162C (hr)
ES (1) ES2833035T3 (hr)
HK (1) HK1173082A1 (hr)
HR (1) HRP20201609T1 (hr)
HU (1) HUE052816T2 (hr)
IL (1) IL217743A (hr)
LT (1) LT2459220T (hr)
MX (1) MX343925B (hr)
MY (1) MY156872A (hr)
NZ (1) NZ597960A (hr)
PL (1) PL2459220T3 (hr)
RU (1) RU2554854C9 (hr)
SG (1) SG177761A1 (hr)
SI (1) SI2459220T1 (hr)
WO (1) WO2011012715A1 (hr)
ZA (1) ZA201200686B (hr)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5732053B2 (ja) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 持続型インスリン組成物
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
KR101756493B1 (ko) 2009-10-29 2017-07-10 아센디스 파마 에이에스 생분해성 하이드로겔의 살균
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
JP2014516946A (ja) * 2011-05-03 2014-07-17 テリック，インコーポレイテッド エザチオスタットとの賦形剤適合性
US11123364B2 (en) * 2011-06-21 2021-09-21 Bvw Holding Ag Medical device comprising boswellic acid
CN103874480A (zh) 2011-08-12 2014-06-18 阿森迪斯药物股份有限公司 前列环素的缓释组合物
WO2013024052A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
US20150010634A1 (en) 2011-10-12 2015-01-08 Ascendis Pharma Ophthamology Division A/S Prevention and treatment of ocular conditions
ES2624626T3 (es) * 2011-11-03 2017-07-17 Bayer Intellectual Property Gmbh Ligadores basados en tirosina para la conexión desprendible de péptidos
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
AU2013254756B2 (en) 2012-04-25 2017-03-30 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
JP6339569B2 (ja) 2012-08-21 2018-06-06 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンへの抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
WO2014031630A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone and use thereof
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
US9394354B2 (en) * 2012-08-21 2016-07-19 Janssen Pharmaceutica Nv Haptens of paliperidone
AU2013328774B2 (en) 2012-10-11 2017-11-30 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
EP2906617B1 (en) 2012-10-11 2018-03-14 Ascendis Pharma A/S Hydrogel prodrugs
MX370543B (es) * 2012-10-11 2019-12-17 Ascendis Pharma Ophthalmology Div A/S Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
AU2013353985B2 (en) 2012-12-07 2017-07-13 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
US20140271885A1 (en) * 2013-03-15 2014-09-18 Intezyne Technologies, Inc. Copolymers for stable micelle formulations
JP6311008B2 (ja) * 2013-04-22 2018-04-11 アセンディス ファーマ エー／エス 修飾されたヒドロゲル
CA2907830C (en) * 2013-04-22 2022-03-29 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
US10130711B2 (en) 2013-06-19 2018-11-20 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
RU2543375C1 (ru) * 2013-07-29 2015-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение производного метилурацила с органической кислотой и способ его получения
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
SG11201601870VA (en) 2013-10-01 2016-04-28 Glaxosmithkline Ip Dev Ltd Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
AU2014333953C1 (en) * 2013-10-08 2020-06-25 Ascendis Pharma A/S Hydrogel-linked IL-1ra prodrug
CN103554296B (zh) * 2013-10-12 2015-09-16 天津大学 一种亚油酸改性葡聚糖及制备高分子脂质体的方法
AU2014345511A1 (en) 2013-11-11 2016-05-12 Ascendis Pharma A/S Relaxin prodrugs
US9675607B2 (en) * 2013-11-13 2017-06-13 Northwestern University Epimorphic regeneration and related hydrogel delivery systems
CN103706233A (zh) * 2013-12-17 2014-04-09 杨亮月 一种环氧乙烷零排放处理体系及方法
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6625550B2 (ja) * 2014-03-14 2019-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｃｏ複合体および治療薬の送達のための方法
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
KR20230173741A (ko) 2014-07-17 2023-12-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 생물의학적 적용을 위한 제어가능한 자기-어닐링 마이크로겔 입자
AU2015299055C1 (en) 2014-08-06 2021-05-06 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9923177B2 (en) * 2014-08-21 2018-03-20 Johnson & Johnson Vision Care, Inc. Biocompatibility of biomedical energization elements
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6723509B2 (ja) 2014-10-24 2020-07-15 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
US11298427B2 (en) 2015-05-29 2022-04-12 Ascendis Pharma A/S Prodrugs comprising a pyroglutamate linker
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
US11458041B2 (en) * 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
AU2016353345B2 (en) 2015-11-12 2021-12-23 University Of Virginia Patent Foundation Compositions and methods for vas-occlusive contraception and reversal thereof
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
US11285103B2 (en) 2015-12-18 2022-03-29 Jie Han Degradable hydrogel under physiological conditions
US10413616B2 (en) 2015-12-23 2019-09-17 Viking Scientific, Inc. Hydrogel prodrug for treatment
WO2017142879A1 (en) 2016-02-16 2017-08-24 The Regents Of The University Of California Methods for immune system modulation with microporous annealed particle gels
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
BR112018017091A2 (pt) 2016-03-01 2019-01-02 Ascendis Pharma Bone Diseases As profármacos de pth
WO2017175200A1 (en) 2016-04-08 2017-10-12 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
CN105963792B (zh) * 2016-04-29 2019-03-22 深圳迈普再生医学科技有限公司 医用水凝胶组合物，医用水凝胶及其制备方法与应用
EP3484523A1 (en) 2016-07-13 2019-05-22 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
MA46428A (fr) 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases As Schéma posologique incrémentiel dans des composés de pth à libération contrôlée
US11759504B2 (en) 2016-09-29 2023-09-19 Ascendis Pharma Bone Diseases A/S PTH compounds with low peak-to-trough ratios
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
JP7189133B2 (ja) 2016-09-29 2022-12-13 アセンディス ファーマ グロース ディスオーダーズ エー／エス 徐放ｃｎｐ作動薬を用いた併用療法
CN117582559A (zh) 2016-12-29 2024-02-23 泰普治疗公司 用于治疗医疗植入物部位的方法和***
CA3055908A1 (en) * 2017-03-10 2018-09-13 University Of Louisville Research Foundation, Inc. Fasl-engineered biomaterials with immunomodulatory function
KR20200007776A (ko) 2017-03-22 2020-01-22 제넨테크, 인크. 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108864258A (zh) * 2017-05-12 2018-11-23 北京康明海慧生物科技有限公司 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN107583104B (zh) * 2017-10-31 2020-12-01 无锡中科光远生物材料有限公司 一种可注射的用于脊柱修复的凝胶材料
EP3703674A4 (en) * 2017-11-02 2021-07-21 Tarsier Pharma Ltd. PHOSPHORYLCHOLINE-TUFTSIN CONJUGATES FOR THE TREATMENT OF EYE INFLAMMATION
CN107880288A (zh) * 2017-11-29 2018-04-06 桂林华诺威生物科技有限公司 一种透明质酸钠凝胶的制备方法
CN108096630B (zh) * 2018-01-29 2020-09-04 暨南大学 一种载淫羊藿苷和去铁胺的聚乳酸基骨组织支架及制备方法和应用
FR3079421A1 (fr) * 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
JP7490563B2 (ja) 2018-03-28 2024-05-27 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ－２コンジュゲート
CN110865130B (zh) * 2018-08-27 2023-08-22 北京海晶生物医药科技有限公司 一种盐酸奥洛他定及其有关物质的检测方法
CA3114329A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN111077235B (zh) * 2018-10-19 2023-09-08 重庆医药工业研究院有限责任公司 一种测定2-[(2-甲基-5-溴苯基)甲基]-5-(4-氟苯基)噻吩杂质的方法
MX2021007707A (es) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Niveles de farmacos locales sostenidos para los agonistas inmunitarios innatos.
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
CA3125533A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Conjugates of pattern recognition receptor agonists
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2020247776A1 (en) * 2019-06-07 2020-12-10 Likarda, LLC Tunable degradation in hydrogel microparticles
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
EP3986478A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
AU2020295721A1 (en) 2019-06-21 2021-12-23 Ascendis Pharma A/S Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds
AU2020296297A1 (en) 2019-06-21 2021-12-16 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
EP3986471A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
EP3990028A4 (en) * 2019-06-26 2023-08-09 Biorchestra Co., Ltd. MICELLAR NANOPARTICLES AND ASSOCIATED USES
WO2021000050A1 (en) * 2019-07-03 2021-01-07 Molly Sandra Shoichet Hydrogel compositions and uses thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
EP4021951A1 (en) * 2019-08-29 2022-07-06 Paul Douglas Godfrin Hydrogels as oral delivery dosage forms, methods of making and using same
TW202128141A (zh) * 2019-11-19 2021-08-01 美商盧伯利索先進材料有限公司 用雙縮二胍鹽化之聚胺酯組成物
AU2020419444A1 (en) 2020-01-03 2022-06-09 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
CN111138293B (zh) * 2020-01-10 2023-07-07 蚌埠丰原医药科技发展有限公司 一种用微通道反应器合成富马酸伊布利特中间体的方法
US20210251893A1 (en) 2020-02-06 2021-08-19 Ocular Therapeutix, Inc. Compositions and Methods for Treating Ocular Diseases
KR102375663B1 (ko) * 2020-03-24 2022-03-16 재단법인대구경북과학기술원 무손실 세포 염색 방법 및 장치
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
AU2021269007A1 (en) 2020-05-04 2022-11-24 Ascendis Pharma A/S Hydrogel irradiation
CN113694261B (zh) * 2020-05-21 2022-09-09 江苏百赛飞生物科技有限公司 一种抗菌复合涂层及其制备方法和制品
US20210369651A1 (en) * 2020-05-28 2021-12-02 Sollievo Pharmaceuticals, Inc Parenteral delivery of avizafone
CA3178074A1 (en) 2020-06-03 2021-12-09 Nina Gunnarsson Il-2 sequences and uses thereof
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4192508A1 (en) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
KR20230057447A (ko) 2020-08-28 2023-04-28 아센디스 파마 온콜로지 디비전 에이/에스 글리코실화된 il-2 단백질 및 이의 용도
AU2021349316A1 (en) 2020-09-28 2023-04-27 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
CN112316156B (zh) * 2020-10-27 2022-03-15 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
KR102437315B1 (ko) * 2020-11-02 2022-08-30 아주대학교산학협력단 하이브리드 하이드로겔 및 이의 생의학적 용도
AU2022246997A1 (en) 2021-04-01 2023-09-28 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
CN113304139B (zh) * 2021-06-30 2022-04-29 贵州医科大学 Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用
CN113398145B (zh) * 2021-07-02 2022-10-14 合肥康诺生物制药有限公司 含nad与氨氯地平的药物组合物及其用途
CN113461979A (zh) * 2021-07-19 2021-10-01 吉林大学 一种通过血红蛋白催化交联的仿贻贝类水凝胶的制备方法
CA3238942A1 (en) 2021-12-13 2023-06-22 Vibeke MILLER BREINHOLT Cancer treatments with tlr7/8 agonists
CN114469926B (zh) * 2022-01-28 2023-06-27 吉林省健维天然生物科技有限公司 二氢槲皮素的新用途及二氢槲皮素水凝胶的制备方法
CN115109275B (zh) * 2022-08-29 2022-11-01 杭州艾名医学科技有限公司 一种动态交联可降解水凝胶、制备方法及应用
CN115444840B (zh) * 2022-09-15 2023-08-25 四川大学 一种前药、两性离子水凝胶及其制备方法、应用
CN115322397B (zh) * 2022-09-23 2024-04-30 福州大学 一种预防术后腹腔粘连的两性离子水凝胶及其制备方法
CN115537017B (zh) * 2022-09-27 2023-09-01 四川大学 一种水凝胶及其制备方法和应用
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024118480A1 (en) * 2022-11-28 2024-06-06 Epiphany Biosciences Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627911B1 (en) 1992-02-28 2000-10-25 Board Of Regents The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
AU2003226166A1 (en) 2002-04-04 2003-10-20 Enzon, Inc. Polymeric acyl derivatives of indoles
CN100418619C (zh) * 2003-01-17 2008-09-17 康乃尔研究基金会有限公司 可注射水凝胶微球和形成水凝胶微球的方法
SI1620118T1 (sl) 2003-04-08 2014-11-28 Yeda Research And Development Co., Ltd. Reverzibilna pegilirana zdravila
AU2004251602B2 (en) 2003-05-23 2010-05-13 Nektar Therapeutics PEG derivatives having an amidocarbonate linkage
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
KR100665672B1 (ko) * 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CA2636957A1 (en) * 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
GB0619175D0 (en) * 2006-09-29 2006-11-08 Univ Nottingham Polymer
EP2099845B1 (en) 2006-11-27 2020-12-23 Actamax Surgical Materials LLC Multi-functional polyalkylene oxides, hydrogels and tissue adhesives
US20080187568A1 (en) * 2007-02-06 2008-08-07 Sawhney Amarpreet S Polymerization with precipitation of proteins for elution in physiological solution
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
SI2237799T1 (sl) 2008-02-01 2019-07-31 Ascendis Pharma A/S Predzdravilo, ki obsega samo-cepljiv linker
AU2009241847B2 (en) * 2008-04-28 2014-07-10 Zogenix, Inc. Novel formulations for treatment of migraine
KR101756493B1 (ko) * 2009-10-29 2017-07-10 아센디스 파마 에이에스 생분해성 하이드로겔의 살균
EP2438930A1 (en) * 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
AU2010277556A1 (en) 2012-02-02
EP2459220A1 (en) 2012-06-06
IL217743A (en) 2017-01-31
CN102573913B (zh) 2014-06-18
HK1173082A1 (en) 2013-05-10
KR101770844B1 (ko) 2017-08-23
JP5904941B2 (ja) 2016-04-20
AU2010277556B2 (en) 2014-10-09
BR112012002280B1 (pt) 2020-04-07
SG177761A1 (en) 2012-03-29
KR20120090039A (ko) 2012-08-16
NZ597960A (en) 2013-07-26
HUE052816T2 (hu) 2021-05-28
SI2459220T1 (sl) 2020-12-31
MY156872A (en) 2016-04-15
EP3782649A1 (en) 2021-02-24
RU2554854C2 (ru) 2015-06-27
ES2833035T3 (es) 2021-06-14
LT2459220T (lt) 2020-12-28
US20120156259A1 (en) 2012-06-21
ZA201200686B (en) 2012-10-31
CN102573913A (zh) 2012-07-11
EP2459220B1 (en) 2020-09-09
WO2011012715A1 (en) 2011-02-03
MX2012001061A (es) 2012-03-26
JP2013500950A (ja) 2013-01-10
CA2769162A1 (en) 2011-02-03
US11559482B2 (en) 2023-01-24
PL2459220T3 (pl) 2021-03-08
RU2012107137A (ru) 2013-09-10
IL217743A0 (en) 2012-03-29
BR112012002280A2 (pt) 2016-06-14
CA2769162C (en) 2017-12-05
MX343925B (es) 2016-11-29
RU2554854C9 (ru) 2017-02-03

Similar Documents

Publication Publication Date Title
HRP20201609T1 (hr) Biorazgradivi hidrogelovi netopivi u vodi bazirani na polietilenglikolu
EP2459227B1 (en) Prodrugs containing an aromatic amine connected by an amide bond to a carrier
CA2636599C (en) Modified macromolecule
EP1585817B1 (en) Conjugates comprising a biodegradable polymer and uses therefor
ES2249824T3 (es) Conjugados de polimeros ramificados no antigenicos.
JP4808610B2 (ja) 薬物および遺伝子のデリバリーシステムとしての多機能性デンドリマーおよびハイパーブランチポリマー
AU2014333954B2 (en) Protecting group comprising a purification tag
Ullah et al. Synthesis of polyphosphazenes with different side groups and various tactics for drug delivery
Ni et al. Recent research progress on polyphosphazene-based drug delivery systems
CA2660842A1 (en) Polyconjugates for in vivo delivery of polynucleotides
Dogan et al. Engineering selective molecular tethers to enhance suboptimal drug properties
Eng et al. Antifouling polymers for nanomedicine and surfaces: recent advances
US10370407B2 (en) Affinity-assisted protein modification and recycling
WO2004093846A2 (en) Charged initiator polymers and methods of use
Khan et al. Poly (organo) phosphazenes: recent progress in the synthesis and applications in tissue engineering and drug delivery
GB2408265A (en) Water-soluble hyperbranched polymer porphyrins
Łażewski et al. Pegylation–in search of balance and enhanced bioavailability
ES2575685T3 (es) Compuestos que consisten en un glucosaminoglucano y un almidón para el transporte de medicamentos o marcadores fluorescentes covalentemente unidos
Franchini et al. Perspectives on: Recent advances in poly (amidoamine) s chemistry
Hoes et al. Design of soluble conjugates of biodegradable polymeric carriers and adriamycin
Constantin et al. Cyclodextrin-containing poly (vinyl alcohol) as non-viral gene delivery systems. 1. Preparation of polymers
Mammadova Cationic thiolated derivatives of poly (aspartic acid) for controlled drug delivery
Kanaujia et al. Polymer Conjugates of Proteins and Drugs to Improve Therapeutics
WO2001007013A2 (en) Thioamide moiety-containing polymer drug conjugates
Sherly et al. Cationic Polyelectrolyte Vectors in Gene Delivery